



# I Quaderni di Orphanet

Collezione Farmaci Orfani

Luglio 2013

## Elenchi dei prodotti medicinali per le malattie rare in Europa

*\*Autorizzazione all'immissione in commercio della Comunità Europea nell'ambito della procedura centralizzata*

[www.orpha.net](http://www.orpha.net)



## Indice generale

### PARTE 1:

<b>Elenco dei prodotti medicinali orfani in Europa con designazione orfana europea e autorizzazione all'immissione in commercio europea</b>	<b>3</b>
Indice	3
Metodologia	3
Classificazione per denominazione commerciale	5
<i>Allegato 1 - Prodotti medicinali orfani rimossi o ritirati dal Registro Europeo dei Prodotti Medicinali Orfani</i>	<i>14</i>
<i>Allegato 2 - Prodotti medicinali orfani ritirati dal commercio nell'Unione Europea</i>	<i>15</i>
Classificazione per data dell'AIC in ordine decrescente	16
Classificazione per categoria ATC	17
Classificazione per titolare dell'AIC	18

### PARTE 2:

<b>Elenco dei prodotti medicinali per le malattie rare in Europa con autorizzazione all'immissione in commercio senza designazione orfana europea</b>	<b>19</b>
Indice	19
Metodologia	19
Classificazione per denominazione commerciale	20
Classificazione per data dell'AIC in ordine decrescente	34
Classificazione per categoria ATC	35
Classificazione per titolare dell'AIC	36

Per qualsiasi domanda o commento, si prega di contattare: [contact.orphanet@inserm.fr](mailto:contact.orphanet@inserm.fr)

## PARTE 1:

# Elenco dei prodotti medicinali orfani in Europa con designazione orfana europea e autorizzazione all'immissione in commercio europea\*

## Indice

<b>Elenco dei prodotti medicinali orfani in Europa con designazione orfana europea e autorizzazione all'immissione in commercio europea</b>	<b>3</b>
Indice	3
Metodologia	3
Classificazione per denominazione commerciale	5
<i>Allegato 1 - Prodotti medicinali orfani rimossi o ritirati dal Registro Europeo dei Prodotti Medicinali Orfani</i>	<i>14</i>
<i>Allegato 2 - Prodotti medicinali orfani ritirati dal commercio nell'Unione Europea</i>	<i>15</i>
Classificazione per data dell'AIC in ordine decrescente	16
Classificazione per categoria ATC	17
Classificazione per titolare dell'AIC	18

## Metodologia

Questa parte del documento fornisce l'elenco di tutti i prodotti medicinali che hanno ottenuto l'autorizzazione all'immissione in commercio (AIC) europea nella data indicata nel documento. Questi prodotti medicinali possono essere accessibili in alcuni paesi europei, ma non necessariamente in tutti. In effetti, l'accessibilità di un determinato prodotto medicinale orfano in un determinato paese dipende dalla strategia intrapresa dal laboratorio e dalle decisioni prese dalle autorità sanitarie nazionali in materia di rimborsi.

I prodotti medicinali orfani in Europa sono prodotti medicinali che hanno ottenuto una designazione orfana europea (secondo il Regolamento (CE) N° 141/2000) e che, in seguito, hanno ottenuto un'autorizzazione all'immissione in commercio europea ed, eventualmente, una valutazione positiva sui benefici rilevanti.

Questo elenco dei prodotti medicinali orfani in Europa con designazione orfana e autorizzazione all'immissione in commercio europea è il risultato del raffronto incrociato dell'elenco dei prodotti medicinali che hanno ottenuto una designazione orfana (<http://ec.europa.eu/health/documents/community-register/html/alforphreg.htm>) con l'elenco dei prodotti medicinali che hanno ottenuto un'autorizzazione all'immissione in commercio (<http://ec.europa.eu/health/documents/>

[community-register/html/alfregister.htm](http://ec.europa.eu/health/documents/community-register/html/alfregister.htm)). Entrambi gli elenchi sono disponibili sul sito della Direzione generale Salute e Consumatori (DG SANCO) della Commissione Europea.

Una prima classificazione per denominazione commerciale fornisce il nome della sostanza attiva, l'indicazione relativa all'autorizzazione all'immissione in commercio, la data e il titolare dell'AIC.

Questa classificazione è seguita da due allegati che comprendono:

- una tabella con i prodotti medicinali orfani rimossi/ritirati dal Registro Comunitario dei Prodotti Medicinali Orfani (vedi Allegato 1 - "Prodotti medicinali orfani rimossi o ritirati dal Registro Comunitario Europeo dei Prodotti Medicinali Orfani"; le indicazioni dei farmaci in questione sono esplicitate nel dettaglio nella Parte II, "Elenco dei prodotti medicinali per le malattie rare in Europa con autorizzazione all'immissione in commercio senza designazione orfana europea");


- una tabella con i prodotti medicinali orfani ritirati dal commercio nell'Unione Europea (vedi Allegato 2 - "Prodotti medicinali ritirati dal commercio nell'Unione Europea"). Maggiori informazioni disponibili su [www.ema.europa.eu](http://www.ema.europa.eu)

\*Autorizzazione all'immissione in commercio dell'Unione Europea mediante procedura centralizzata

Tre elenchi aggiuntivi propongono altre classificazioni per:

- Data dell'AIC in ordine decrescente;
- Categoria ATC;
- Titolare dell'AIC.

In ciascun elenco, le denominazione commerciali sono disposte in ordine alfabetico.

Ulteriori informazioni sono disponibili nella sezione "Farmaci orfani" del sito web di Orphanet, [www.orpha.net](http://www.orpha.net), o sul sito web dell'EMA (Agenzia Europea per i Medicinali) <http://www.ema.europa.eu>. Gli elenchi forniti dall'EMA non comprendono solo i prodotti medicinali orfani ma tutti i prodotti medicinali autorizzati all'immissione in commercio. I prodotti medicinali orfani con designazione orfana europea sono contrassegnati da un logo .



Informazioni ufficiali aggiornate sui prodotti medicinali orfani sono disponibili nel Registro comunitario dei prodotti medicinali orfani per uso umano:

<http://ec.europa.eu/health/documents/community-register/html/alforphreg.htm>

## Classificazione per denominazione commerciale

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
ADCETRIS	Brentuximab vedotin	*Treatment of adult patients with relapsed or refractory CD30+ <b>Hodgkin lymphoma</b> (HL): 1. following autologous stem cell transplant (ASCT) or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. *Treatment of adult patients with relapsed or refractory systemic <b>anaplastic large cell lymphoma</b> (sALCL).	25/10/2012	Takeda Global Research and Development Centre (Europe) Ltd
ARZERRA	Ofatumumab	Treatment of <b>chronic lymphocytic leukaemia</b> (CLL) in patients who are refractory to fludarabine and alemtuzumab.	19/04/2010	Glaxo Group Ltd
ATRIANCE	Nelarabine	Treatment of patients with <b>T-cell acute lymphoblastic leukaemia</b> (T-ALL) and <b>T-cell lymphoblastic lymphoma</b> (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.	22/08/2007	Glaxo Group Ltd
BOSULIF	Bosutinib	Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) <b>Philadelphia chromosome positive chronic myelogenous leukaemia</b> (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.	27/03/2013	Pfizer Ltd
BRONCHITOL	Mannitol	For the treatment of <b>cystic fibrosis</b> (CF) in adults aged 18 years and above as an add-on therapy to best standard of care.	13/04/2012	Pharmaxis Pharmaceuticals Limited
CARBAGLU	Carglumic acid	Treatment of <b>hyperammonaemia</b> due to <b>N-acetylglutamate synthase primary deficiency</b> , hyperammonaemia due to <b>isovaleric acidaemia</b> , hyperammonaemia due to <b>methymalonic acidaemia</b> , hyperammonaemia due to <b>propionic acidaemia</b> . <i>This orphan designated product has completed its 10 years of "market exclusivity" for its indication in hyperammonaemia due to N-acetylglutamate synthetase (NAGS) deficiency.</i>	24/01/2003	Orphan Europe S.a.r.l.
CAYSTON	Aztreonam	Suppressive therapy of chronic pulmonary infections due to <i>Pseudomonas aeruginosa</i> in patients with <b>cystic fibrosis</b> (CF) aged 6 years and older.	21/09/2009	Gilead Sciences International Limited

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
CEPLENE	Histamine dihydrochloride	Maintenance therapy for adult patients with <b>acute myeloid leukaemia</b> in first remission concomitantly treated with interleukin-2 (IL-2). The efficacy of Ceplene has not been fully demonstrated in patients older than age 60.	07/10/2008	Meda AB
CYSTADANE	Betaine anhydrous	Adjunctive treatment of <b>homocystinuria</b> , involving deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylene-tetrahydrofolate reductase (MTHFR), cobalamin cofactor metabolism (cbl). Cystadane should be used as supplement to other therapies such as vitamin B6 (pyridoxine), vitamin B12 (cobalamin), folate and a specific diet.	15/02/2007	Orphan Europe S.a.r.l.
DACOGEN	Decitabine	Treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary <b>acute myeloid leukaemia</b> (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy.	20/09/2012	Janssen-Cilag International N V
DIACOMIT	Stiripentol	Use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with <b>severe myoclonic epilepsy in infancy</b> (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.	04/01/2007	Biocodex
ELAPRASE	Idursulfase	Long-term treatment of patients with <b>Hunter syndrome</b> (Mucopolysaccharidosis II, MPS II).	08/01/2007	Shire Human Genetic Therapies AB
ESBRIET	Pirfenidone	In adults for the treatment of mild to moderate <b>Idiopathic Pulmonary Fibrosis</b> (IPF).	28/02/2011	InterMune UK Ltd.
EVOLTRA	Clofarabine	Treatment of <b>acute lymphoblastic leukaemia</b> (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients $\leq$ 21 years old at initial diagnosis.	29/05/2006	Genzyme Europe B.V.
EXJADE	Deferasirox	*Treatment of chronic iron overload due to frequent blood transfusions ( $\geq$ 7 ml/kg/month of packed red blood cells) in patients with <b>beta thalassaemia major</b> aged 6 years and older. *Treatment of <b>chronic iron overload</b> due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups: - in patients with beta thalassaemia major with iron overload due to frequent blood transfusions in ( $\geq$ 7 ml/kg/month of packed red blood cells) patients aged 2 to 5 years - in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions ( $<$ 7 ml/kg/month of packed red blood cells) aged 2 years and older, - in patients with other anaemias aged 2 years and older.	28/08/2006	Novartis Europharm Ltd

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
FIRAZYR	Icatibant acetate	Symptomatic treatment of acute attacks of <b>hereditary angioedema (HAE)</b> in adults (with C1-esterase-inhibitor deficiency).	11/07/2008	Shire Orphan Therapies GmbH
FIRDAPSE (ex-ZENAS)	Amifampridine	Symptomatic treatment of <b>Lambert-Eaton myasthenic syndrome (LEMS)</b> in adults.	23/12/2009	Biomarin Europe Ltd
GLIOLAN	5-aminolevulinic acid hydrochloride	In adult patients for visualisation of malignant tissue during surgery for <b>malignant glioma</b> (World Health Organization grade III and IV).	07/09/2007	Medac GmbH
GLYBERA	Alipogene tiparvovec	For adult patients diagnosed with <b>familial lipoprotein lipase deficiency (LPLD)</b> and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. The diagnosis of LPLD has to be confirmed by genetic testing. The indication is restricted to patients with detectable levels of LPL protein.	29/10/2012	uniQure bio-pharma B.V.
ICLUSIG	Ponatinib	Iclusig is indicated in adult patients with : - chronic phase, accelerated phase, or blast phase <b>chronic myeloid leukaemia (CML)</b> who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation ; - <b>Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL)</b> who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.	01/07/2013	ARIAD Pharma Ltd
INCRELEX	Mecasermin	Long-term treatment of <b>growth failure</b> in children and adolescents with severe <b>primary insulin-like growth factor 1 deficiency (Primary IGFD)</b> .	03/08/2007	Ipsen Pharma
INOVELON	Rufinamide	Adjunctive therapy in the treatment of seizures associated with <b>Lennox Gastaut syndrome</b> in patients aged 4 years and older.	16/01/2007	Eisai Ltd
JAKAVI	Ruxolitinib	Treatment of disease-related splenomegaly or symptoms in adult patients with <b>primary myelofibrosis</b> (also known as chronic idiopathic myelofibrosis), <b>post-polycythaemia-vera myelofibrosis</b> or <b>post-essential-thrombocythaemia myelofibrosis</b> .	23/08/2012	Novartis Euro-pharm Ltd
KALYDECO	Ivacaftor	Kalydeco is indicated for the treatment of <b>cystic fibrosis (CF)</b> in patients age 6 years and older who have a <i>G551D</i> mutation in the <i>CFTR</i> gene.	23/07/2012	Vertex Pharmaceuticals (U.K.) Limited
KUVAN	Sapropterin dihydrochloride	*Treatment of hyperphenylalaninaemia (HPA) in adult and paediatric patients of 4 years of age and over with <b>phenylketonuria (PKU)</b> who have been shown to be responsive to such treatment *Treatment of hyperphenylalaninaemia (HPA) in adult and paediatric patients with <b>tetrahydrobiopterin (BH4) deficiency</b> who have been shown to be responsive to such treatment.	02/12/2008	Merck Serono Europe Ltd

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
LITAK	Cladribine (subcutaneous use)	Treatment of <b>hairy cell leukaemia</b> .	14/04/2004	Lipomed GmbH
LYSODREN	Mitotane	Symptomatic treatment of advanced (unresectable, metastatic or relapsed) <b>adrenal cortical carcinoma</b> .	28/04/2004	Laboratoire HRA Pharma
MEPACT	Mifamurtide	In children, adolescents and young adults for the treatment of high-grade resectable non-metastatic <b>osteosarcoma</b> after macroscopically complete surgical resection. It is used in combination with post-operative multi-agent chemotherapy.	06/03/2009	IDM Pharma SAS
MOZOBIL	Plerixafor	In combination with G-CSF to enhance mobilisation of <b>haematopoietic stem cells</b> to the peripheral blood for collection and subsequent <b>autologous transplantation</b> in patients with <b>lymphoma</b> and <b>multiple myeloma</b> whose cells mobilise poorly.	31/07/2009	Genzyme Europe B.V.
MYOZYME	Recombinant human acid alpha-glucosidase INN = Alglucosidase alpha	Long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of <b>Pompe disease</b> (acid $\alpha$ -glucosidase deficiency).	29/03/2006	Genzyme Europe B.V.
NAGLAZYME	N-acetylgalactosamine-4-sulfatase INN = Galsulfase	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of <b>Mucopolysaccharidosis VI</b> (MPS VI; N-acetylgalactosamine 4-sulfatase deficiency; Maroteaux-Lamy syndrome).	24/01/2006	BioMarin Europe Ltd
NEXAVAR	Sorafenib tosylate	*Treatment of <b>hepatocellular carcinoma</b> *Treatment of patients with advanced <b>renal cell carcinoma</b> who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.	19/07/2006	Bayer Pharma AG
NEXOBRID	Concentrate of proteolytic enzymes enriched in bromelain	Removal of eschar in adults with <b>deep partial- and full-thickness thermal burns</b> .	18/12/2012	Teva Pharma GmbH
NPLATE	Romiplostim	Adult chronic <b>immune (idiopathic) thrombocytopenic purpura</b> (ITP) in splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Nplate may be considered as second line treatment for adult non-splenectomised patients where surgery is contra-indicated.	04/02/2009	Amgen Europe B.V.
ORFADIN	Nitisinone	Treatment of patients with confirmed diagnosis of <b>hereditary tyrosinemia type 1</b> (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.	21/02/2005	Swedish Orphan Biovitrum International AB
PEDEA	Ibuprofen	Treatment of a haemodynamically significant <b>patent ductus arteriosus</b> in preterm newborn infants less than 34 weeks of gestational age.	29/07/2004	Orphan Europe S.a.r.l.
PEYONA (ex-NYMUSA)	Caffeine citrate	Treatment of <b>primary apnea</b> of premature newborns.	02/07/2009	Chiesi Farmaceutici SpA



TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
PLENADREN	Hydrocortisone	Treatment of <b>adrenal insufficiency</b> in adults.	03/11/2011	ViroPharma SPRL
PRIALT	Ziconotide (intraspinale use)	Treatment of severe, <b>chronic pain</b> in patients who require <b>intrathecal (IT) analgesia</b> .	21/02/2005	Eisai Ltd
REVATIO	Sildenafil citrate	*Treatment of adult patients with <b>pulmonary arterial hypertension</b> classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. *Treatment of paediatric patients aged 1 year to 17 years old with <b>pulmonary arterial hypertension</b> . Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease. Revatio solution for injection is for the treatment of adult patients with pulmonary arterial hypertension who are currently prescribed oral Revatio and who are temporarily unable to take oral therapy, but are otherwise clinically and haemodynamically stable.	28/10/2005	Pfizer Ltd
REVESTIVE	Teduglutide	Treatment of adult patients with <b>Short Bowel Syndrome</b> . Patients should be stable following a period of intestinal adaptation after surgery.	30/08/2012	Nycomed Danmark ApS
REVLIMID	Lenalidomide	In combination with dexamethasone, treatment of <b>multiple myeloma</b> in adult patients who have received at least one prior therapy.	14/06/2007	Celgene Europe Ltd
SAVENE	Dexrazoxane	In adults for the treatment of <b>anthracycline extravasation</b> .	28/07/2006	SpePharm Holding B.V.
SIGNIFOR	Pasireotide	Treatment of adult patients with <b>Cushing's disease</b> for whom surgery is not an option or for whom surgery has failed.	24/04/2012	Novartis Europharm Ltd
SIKLOS	Hydroxycarbamide	Prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic <b>Sickle Cell Syndrome</b> .	29/06/2007	Addmedica
SOLIRIS	Eculizumab	For the treatment of adults and children with : - <b>paroxysmal nocturnal haemoglobinuria (PNH)</b> . Evidence of clinical benefit of Soliris in the treatment of patients with PNH is limited to patients with history of transfusions; - <b>atypical haemolytic uraemic syndrome (aHUS)</b> .	20/06/2007	Alexion Europe SAS
SPRYCEL	Dasatinib	Treatment of adult patients with: - newly diagnosed Philadelphia chromosome positive (Ph+) <b>chronic myelogenous leukaemia (CML)</b> in the chronic phase. - chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate. - Ph+ <b>acute lymphoblastic leukaemia (ALL)</b> and lymphoid blast CML with resistance or intolerance to prior therapy.	20/11/2006	Bristol-Myers Squibb Pharma EEIG

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
TASIGNA	Nilotinib	<p>* Tasigna 150 mg Treatment of adult patients with newly diagnosed Philadelphia-chromosome-positive <b>chronic myelogenous leukaemia (CML)</b> in the chronic phase.</p> <p>* Tasigna 200 mg Treatment of adult patients with : - newly diagnosed Philadelphia-chromosome-positive <b>CML</b> in the chronic phase; - chronic phase and accelerated phase Philadelphia-chromosome-positive <b>CML</b> with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available.</p>	19/11/2007	Novartis Euro-pharm Ltd
TEPADINA	Thiotepa	<p>In combination with other chemotherapy medicinal products: 1) with or without total body irradiation (TBI), as conditioning treatment prior to <b>allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT)</b> in haematological diseases in adult and paediatric patients; 2) when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients. It is proposed that Tepadina must be prescribed by physicians experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation.</p>	15/03/2010	Adienne S.r.l.
THALIDOMIDE CELGENE	Thalidomide	<p>In combination with melphalan and prednisone as first line treatment of patients with untreated <b>multiple myeloma</b>, aged <math>\geq 65</math> years or ineligible for high dose chemotherapy.</p>	16/04/2008	Celgene Europe Ltd
TOBI PODHALER	Tobramycin	<p>Suppressive therapy of chronic pulmonary infection due to <i><b>Pseudomonas aeruginosa</b></i> in adults and children aged 6 years and older with <b>cystic fibrosis</b>.</p>	20/07/2011	Novartis Europharm Limited
TORISEL	Temsirolimus	<p>*First-line treatment of adult patients with advanced <b>renal cell carcinoma (RCC)</b> who have at least three of six prognostic risk factors. *Treatment of adult patients with relapsed and / or refractory <b>mantle cell lymphoma (MCL)</b>.</p>	19/11/2007	Pfizer Limited

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
TRACLEER	Bosentan monohydrate	<p>* Treatment of <b>pulmonary arterial hypertension</b> (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in :</p> <ul style="list-style-type: none"> <li>- primary (idiopathic and heritable) PAH,</li> <li>- PAH secondary to scleroderma without significant interstitial pulmonary disease,</li> <li>- PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology.</li> </ul> <p>Some improvements have also been shown in patients with PAH WHO functional class II.</p> <p>* To reduce the number of new digital ulcers in patients with <b>systemic sclerosis</b> and ongoing digital ulcer disease.</p> <p><i>This orphan designated product has completed its 10 years of "market exclusivity" for its indication in pulmonary arterial hypertension.</i></p>	15/05/2002	Actelion Registration Ltd
VENTAVIS	Iloprost	Treatment of patients with <b>primary pulmonary hypertension</b> , classified as NYHA functional class III, to improve exercise capacity and symptoms.	16/09/2003	Bayer Pharma AG
VIDAZA	Azacitidine	Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with: <ul style="list-style-type: none"> <li>- intermediate-2 and high-risk <b>myelodysplastic syndromes</b> (MDS) according to the International Prognostic Scoring System (IPSS),</li> <li>- <b>chronic myelomonocytic leukaemia</b> (CMML) with 10-29% marrow blasts without myeloproliferative disorder,</li> <li>- <b>acute myeloid leukaemia</b> (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification.</li> </ul>	17/12/2008	Celgene Europe Ltd
VOLIBRIS	Ambrisentan	Treatment of patients with <b>pulmonary arterial hypertension</b> (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.	21/04/2008	Glaxo Group Ltd
VOTUBIA	Everolimus	<p>* Treatment of adult patients with <b>renal angiomyolipoma</b> associated with <b>tuberous sclerosis complex</b> (TSC) who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery. The evidence is based on analysis of change in sum of angiomyolipoma volume.</p> <p>* Treatment of patients aged 3 years and older with <b>subependymal giant cell astrocytoma</b> (SEGA) associated with <b>tuberous sclerosis complex</b> (TSC) who require therapeutic intervention but are not amenable to surgery. The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease-related symptoms, has not been demonstrated.</p>	02/09/2011	Novartis Europharm Ltd

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
VPRIV	Velaglucerase alfa	Long-term enzyme replacement therapy (ERT) in patients with <b>type 1 Gaucher disease</b> .	26/08/2010	Shire Pharmaceuticals Ireland Ltd
VYNDAQEL	Tafamidis	Treatment of <b>transthyretin amyloidosis</b> in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment.	16/11/2011	Pfizer Ltd
WILZIN	Zinc acetate dihydrate	Treatment of <b>Wilson's disease</b> .	13/10/2004	Orphan Europe S.a.r.l.
XAGRID	Anagrelide hydrochloride	Reduction of elevated platelet counts in at-risk <b>essential-thrombocythaemia (ET)</b> patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. <b>An at-risk patient</b> An at risk ET is defined by one or more of the following features: - > 60 years of age or - a platelet count > 1000 x 10 <sup>9</sup> /l or - a history of thrombo-haemorrhagic events.	16/11/2004	Shire Pharmaceutical Contracts Ltd
XALUPRINE (ex-MERCAPTOPURINE NOVA)	Mercaptopurine	Treatment of <b>acute lymphoblastic leukaemia (ALL)</b> in adults, adolescents and children.	09/03/2012	Nova Laboratories Ltd
YONDELIS	Trabectedin	*Treatment of patients with advanced <b>soft tissue sarcoma</b> , after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on <b>liposarcoma</b> and <b>leiomyosarcoma</b> patients. *In combination with pegylated liposomal doxorubicin (PLD), treatment of patients with relapsed platinum-sensitive <b>ovarian cancer</b> .	17/09/2007	Pharma Mar S.A.
ZAVESCA	Miglustat	*Oral treatment of adult patients with mild to moderate <b>type 1 Gaucher disease</b> . Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable *Treatment of progressive neurological manifestations in adult patients and paediatric patients with <b>Niemann-Pick type C disease</b> . <i>This orphan designated product has completed its 10 years of "market exclusivity" for its indication in Gaucher Disease.</i>	20/11/2002	Actelion Registration Ltd

## Allegato 1

### Prodotti medicinali orfani rimossi o ritirati dal Registro Europeo dei Prodotti Medicinali Orfani

[Cf. Parte II "Elenco dei prodotti medicinali per le malattie rare in Europa con autorizzazione all'immissione in commercio\\* senza designazione orfana europea".](#)

TRADENAME	ACTIVE SUBSTANCE	REGULAR STATUS
AFINITOR	Everolimus	This product is no longer an orphan medicine. It was originally designated an orphan medicine on 5 June 2007. Upon request of the marketing authorisation holder, Afinitor has now been removed from the Community Register of orphan medicinal products.
ALDURAZYME	Laronidase	This product is no longer an orphan medicine. It was originally designated an orphan medicine on 14 February 2001. Aldurazyme was withdrawn from the Community register of orphan medicinal products in June 2013 at the end of the period of market exclusivity.
BUSILVEX	Busulfan	This product is no longer an orphan medicine. It was originally designated an orphan medicine on 29 December 2001. Busilvex was withdrawn from the Community register of orphan medicinal products in July 2013 at the end of the period of market exclusivity.
FABRAZYME	Recombinant human alphagalactosidase A INN = Agalsidase beta	This product is no longer an orphan medicine. It was originally designated an orphan medicine on 8 August 2000. Fabrazyme was withdrawn from the Community register of orphan medicinal products in August 2011 at the end of the period of market exclusivity.
GLIVEC	Imatinib mesilate	This product is no longer an orphan medicine. It was originally designated an orphan medicine for the following conditions: <ul style="list-style-type: none"> <li>- treatment of chronic myeloid leukaemia (14/02/2001);</li> <li>- treatment of malignant gastrointestinal stromal tumours (20/11/2001);</li> <li>- treatment of dermatofibrosarcoma protuberans (26/08/2005);</li> <li>- treatment of acute lymphoblastic leukaemia (26/08/2005);</li> <li>- treatment of chronic eosinophilic leukaemia and the hypereosinophilic syndrome (28/10/2005);</li> <li>- treatment of myelodysplastic / myeloproliferative diseases (23/12/2005).</li> </ul> Upon request of the marketing-authorisation holder, Glivec has now been removed from the Community register of orphan medicinal products.
ILARIS	Canakinumab	This product is no longer an orphan medicine. It was originally designated an orphan medicine on 20 March 2007. Upon request of the marketing authorisation holder, Ilaris has now been removed from the Community Register of orphan medicinal products.
NOVOTHIRTEEN	Catridecacog	This product is no longer an orphan medicine. It was originally designated an orphan medicine on 12 December 2003. Upon request of the marketing-authorisation holder, NovoThirteen has now been removed from the Community Register of orphan medicinal products.
REPLAGAL	Agalsidase alfa	This product is no longer an orphan medicine. It was originally designated an orphan medicine on 8 August 2000. Replagal was withdrawn from the Community register of orphan medicinal products in August 2011 at the end of the period of market exclusivity.
REVOLADE	Eltrombopag	This product is no longer an orphan medicine. It was originally designated an orphan medicine on 3 August 2007. Upon request of the marketing authorisation holder, Revolade has now been removed from the Community Register of orphan medicinal products.

TRADENAME	ACTIVE SUBSTANCE	REGULAR STATUS
SOMAVERT	Pegvisomant	This product is no longer an orphan medicine. It was originally designated an orphan medicine on 14 February 2001. Somavert was withdrawn from the Community register of orphan medicinal products in November 2012 at the end of the period of market exclusivity.
SUTENT	Sunitinib malate	This product is no longer an orphan medicine. This product was originally an orphan designated on 10 March 2005. Upon request of the marketing authorisation holder, Sutent has now been removed from the Community register of orphan medicinal products.
TRISENOX	Arsenic trioxide	This product is no longer an orphan medicine. It was originally designated an orphan medicine on 18 October 2000. Trisenox was withdrawn from the Community register of orphan medicinal products in March 2012 at the end of the 10-year period of market exclusivity.
XYREM	Sodium oxybate	This product is no longer an orphan medicine. This product was originally an orphan designated on 3 February 2003. Upon request of the marketing authorisation holder, Xyrem has now been removed from the Community register of orphan medicinal products.

## Allegato 2


### *Prodotti medicinali orfani ritirati dal commercio nell'Unione Europea*

Ulteriori informazioni sul sito [www.ema.europa.eu](http://www.ema.europa.eu)

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION (MA) INDICATION	MA DATE / MA HOLDER	MA WITH-DRAWN DATE
ONSENAL	Celecoxib	Reduction of the number of adenomatous intestinal polyps in <b>familial adenomatous polyposis (FAP)</b> , as an adjunct to surgery and further endoscopic surveillance.	17/10/2003 Pfizer Ltd	24/03/2011
PHOTOBARR	Porfimer sodium (for use with photodynamic therapy)	Ablation of high-grade dysplasia (HGD) in patients with <b>Barrett's Oesophagus</b> .	25/03/2004 Pinnacle Biologics B.V.	20/04/2012
RILONACEPT REGENERON (ex-ARCALYST)	Rilonacept	Treatment of <b>Cryopyrin-Associated Periodic Syndromes (CAPS)</b> with severe symptoms, including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children aged 12 years and older.	23/10/2009 Regeneron UK Limited	24/10/2012
THELIN	Sitaxentan sodium	Treatment of patients with <b>pulmonary arterial hypertension</b> classified as WHO functional class III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease.	10/08/2006 Pfizer Ltd	06/01/2011

## Classificazione per data dell'AIC in ordine decrescente


<b>2013</b>	<b>2009</b>	SIKLOS	<b>2004</b>
BOSULIF	CAYSTON	SOLIRIS	LITAK
ICLUSIG	FIRDAPSE	TASIGNA	LYSODREN
<b>2012</b>	MEPACT	TORISEL	PEDEA
ADCETRIS	MOZOBIL	YONDELIS	WILZIN
BRONCHITOL	NPLATE	<b>2006</b>	XAGRID
DACOGEN	PEYONA	EVOLTRA	<b>2003</b>
GLYBERA	<b>2008</b>	EXJADE	CARBAGLU
JAKAVI	CEPLENE	MYOZYME	VENTAVIS
KALYDECO	FIRAZYR	NAGLAZYME	<b>2002</b>
NEXOBRID	KUVAN	NEXAVAR	TRACLEER
REVESTIVE	THALIDOMIDE CELGENE	SAVENE	ZAVESCA
SIGNIFOR	VIDAZA	SPRYCEL	
XALUPRINE	VOLIBRIS	<b>2005</b>	
<b>2011</b>	<b>2007</b>	ORFADIN	
ESBRIET	ATRIANCE	PRIALT	
PLENADREN	CYSTADANE	REVATIO	
TOBI PODHALER	DIACOMIT		
VOTUBIA	ELAPRASE		
VYNDAQEL	GLIOLAN		
<b>2010</b>	INCRELEX		
ARZERRA	INOVELON		
TEPADINA	REVLIMID		
VPRIV			



## Classificazione per categoria ATC

<b>A- ALIMENTARY TRACT AND METABOLISM</b>	<b>G- GENITO URINARY SYSTEM AND SEX HORMONES</b>	ICLUSIG	<b>N- NERVOUS SYSTEM</b>
CARBAGLU	REVATIO	JAKAVI	DIACOMIT
CYSTADANE	<b>H- SYSTEMIC HORMONAL PREPARATIONS, EXCL, SEX HORMONES AND INSULINS</b>	LITAK	FIRDAPSE (ex-ZENAS)
ELAPRASE	INCRELEX	LYSODREN	INOVELON
KUVAN	PLENADREN	MEPACT	PEYONA (ex-NYMUSA)
MYOZYME	SIGNIFOR	MOZOBIL	PRIALT
NAGLAZYME	<b>J- GENERAL ANTIINFECTIVES FOR SYSTEMIC USE</b>	NEXAVAR	VYNDAQEL
ORFADIN	CAYSTON	REVLIMID	<b>R- RESPIRATORY SYSTEM</b>
REVESTIVE	TOBI PODHALER	SIKLOS	BRONCHITOL
VPRIV	<b>L- ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</b>	SOLIRIS	KALYDECO
WILZIN	ADCETRIS	SPRYCEL	<b>V- VARIOUS</b>
ZAVESCA	ARZERRA	TASIGNA	EXJADE
<b>B- BLOOD AND BLOOD FORMING ORGANS</b>	ATRIANCE	TEPADINA	SAVENE
NPLATE	BOSULIF	THALIDOMIDE	<b>ATC CODE NOT YET ASSIGNED</b>
VENTAVIS	CEPLENE	CELGENE	NEXOBRID
<b>C- CARDIOVASCULAR SYSTEM</b>	DACOGEN	TORISEL	
FIRAZYR	ESBRIET	VIDAZA	
GLYBERA	EVOLTRA	VOTUBIA	
PEDEA	GLIOLAN	XAGRID	
TRACLEER		XALUPRINE	
VOLIBRIS		YONDELIS	

Numero dei farmaci orfani in Europa con designazione orfana europea e autorizzazione all'immissione in commercio europea per categoria ATC





## Classificazione per titolare dell'AIC

<b>ACTELION REGISTRATION LTD</b>	<b>GENZYME EUROPE B.V.</b>	<b>NOVARTIS EUROPHARM LTD</b>	<b>SPEPHARM HOLDING BV</b>
TRACLEER	EVOLTRA	EXJADE	SAVENE
ZAVESCA	MOZOBIL	JAKAVI	<b>SWEDISH ORPHAN BIOVITRUM INTERNATIONAL AB</b>
<b>ADDMEDICA</b>	MYOZYME	SIGNIFOR	ORFADIN
SIKLOS	<b>GILEAD SCIENCES INTERNATIONAL LTD</b>	TASIGNA	<b>TAKEDA GLOBAL RESEARCH AND DEVELOPMENT CENTRE (EUROPE) LTD</b>
<b>ADIENNE SRL</b>	CAYSTON	TOBI PODHALER	ADCETRIS
TEPADINA	<b>GLAXO GROUP LTD</b>	VOTUBIA	<b>TEVA PHARMA GMBH</b>
<b>ALEXION EUROPE SAS</b>	ARZERRA	<b>NYCOMED DANMARK APS</b>	NEXOBRID
SOLIRIS	ATRIANCE	REVESTIVE	<b>UNIQUIRE BIOPHARMA B.V.</b>
<b>AMGEN EUROPE B.V.</b>	VOLIBRIS	<b>ORPHAN EUROPE S.A.R.L</b>	GLYBERA
NPLATE	<b>IDM PHARMA SAS</b>	CARBAGLU	<b>VERTEX PHARMACEUTICALS (U.K.) LTD</b>
<b>ARIAD PHARMA LTD</b>	MEPACT	CYSTADANE	KALYDECO
ICLUSIG	<b>INTERMUNE UK LTD</b>	PEDEA	<b>VIROPHARMA SPRL</b>
<b>BAYER PHARMA AG</b>	ESBRIET	WILZIN	PLENADREN
NEXAVAR	<b>IPSEN PHARMA</b>	<b>PFIZER LTD</b>	
VENTAVIS	INCRELEX	BOSULIF	
<b>BIOCODEX</b>	<b>JANSSEN-CILAG INTERNATIONAL NV</b>	REVATIO	
DIACOMIT	DACOGEN	TORISEL	
<b>BIOMARIN EUROPE LTD</b>	<b>LABORATOIRE HRA PHARMA</b>	VYNDAQEL	
FIRDAPSE	LYSODREN	<b>PHARMA MAR S.A.</b>	
NAGLAZYME	<b>LIPOMED GMBH</b>	YONDELIS	
<b>BRISTOL MYERS SQUIBB EEIG</b>	LITAK	<b>PHARMAXIS PHARMACEUTICALS LTD</b>	
SPRYCEL	<b>MEDA AB</b>	BRONCHITOL	
<b>CELGENE EUROPE LTD</b>	CEPLENE	<b>SHIRE HUMAN GENETIC THERAPIES AB</b>	
REVLIMID	<b>MEDAC GMBH</b>	ELAPRASE	
THALIDOMIDE CELGENE	GLIOLAN	<b>SHIRE ORPHAN THERAPIES GMBH</b>	
VIDAZA	<b>MERCK SERONO EUROPE LTD</b>	FIRAZYR	
<b>CHIESI FARMACEUTICI SPA</b>	KUVAN	XAGRID	
PEYONA	<b>NOVA LABORATORIES LTD</b>	<b>SHIRE PHARMACEUTICALS IRELAND LTD</b>	
<b>ESAI LTD</b>	XALUPRINE	VPRIV	
INOVELON			
PRIALT			

## PARTE 2:

# Elenco dei prodotti medicinali per le malattie rare in Europa con autorizzazione all'immissione in commercio\* senza designazione orfana europea

## Indice

### Elenco dei prodotti medicinali per le malattie rare in Europa con autorizzazione all'immissione in commercio\* (senza designazione orfana europea) **17**

Metodologia	17
Per denominazione commerciale	18
Per data dell'AIC in ordine decrescente	32
Per categoria ATC	33
Per titolare dell'AIC	34

## Metodologia

Questa parte del documento fornisce l'elenco di tutti i prodotti medicinali per le malattie rare che hanno ottenuto l'autorizzazione all'immissione in commercio (AIC) europea per una o più indicazioni terapeutiche per una malattia rara, ma che non hanno ottenuto una designazione orfana europea o per i quali la designazione è stata ritirata.

Questi prodotti medicinali possono avere ottenuto (o non ottenuto) una designazione orfana in un'altra area geografica del mondo e sono disponibili nell'elenco fornito dalla DG Sanco relativo ai prodotti medicinali che hanno ottenuto l'autorizzazione all'immissione in commercio: <http://ec.europa.eu/health/documents/communityregister/html/alfregister.htm>

Una prima classificazione per denominazione commerciale fornisce il nome della sostanza attiva,

l'indicazione "rara" dell'autorizzazione all'immissione in commercio, la data e il titolare dell'AIC.

Tre elenchi aggiuntivi propongono altre classificazioni per:

- Data dell'AIC in ordine decrescente;
- Categoria ATC;
- Titolare dell'AIC.

In ciascun elenco, le denominazioni commerciali sono disposte in ordine alfabetico.

Ulteriori informazioni sono disponibili nella sezione "Farmaci orfani" del sito web di Orphanet, [www.orpha.net](http://www.orpha.net), o sul sito web dell'EMA (Agenzia Europea per i Medicinali) <http://www.ema.europa.eu>.

\*Autorizzazione all'immissione in commercio dell'Unione Europea mediante procedura centralizzata

## Classificazione per denominazione commerciale

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
ADCIRCA	Tadalafil	In adults for the treatment of <b>pulmonary arterial hypertension</b> (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.	01/10/2008	Eli Lilly Nederland B.V.
ADVATE	Octocog alpha	Treatment and prophylaxis of bleeding in patients with <b>haemophilia A</b> (congenital factor VIII deficiency). Advate does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease.	02/03/2004	Baxter AG
AFINITOR	Everolimus	*Treatment of unresectable or metastatic, well- or moderately-differentiated <b>neuroendocrine tumours of pancreatic origin</b> in adults with progressive disease. *Treatment of patients with advanced <b>renal cell carcinoma</b> , whose disease has progressed on or after treatment with VEGF-targeted therapy.	03/08/2009	Novartis Europharm Ltd
ALDURAZYME	Laronidase	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of <b>Mucopolysaccharidosis I</b> (MPS I; a [alpha]-L-iduronidase deficiency) to treat the non-neurological manifestations of the disease.	10/06/2003	Genzyme Europe B.V.
ALIMTA	Pemetrexed	In combination with cisplatin for the treatment of chemotherapy naïve patients with unresectable malignant pleural <b>mesothelioma</b> .	20/09/2004	Eli Lilly Nederland B.V.
AMMONAPS	Sodium phenylbutyrate	Adjunctive therapy in the chronic management of <b>urea cycle disorders</b> , involving deficiencies of carbamyl phosphate synthetase, ornithine transcarbamylase, or argininosuccinate synthetase. It is indicated in all patients with <i>neonatal-onset</i> presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with <i>late-onset</i> disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy.	08/12/1999	Swedish Orphan Biovitrum International AB
ATRYN	Antithrombin alpha	Prophylaxis of venous thromboembolism in surgery of adult patients with <b>congenital antithrombin deficiency</b> . Atryn is normally given in association with heparin or low molecular weight heparin.	28/07/2006	GTC Biotherapeutics UK Limited

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
AVASTIN	Bevacizumab	<p>* In combination with interferon alfa-2a for first line treatment of adult patients with advanced and/or metastatic <b>renal cell cancer</b>.</p> <p>* In combination with carboplatin and paclitaxel for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) <b>epithelial ovarian, fallopian tube, or primary peritoneal cancer</b>.</p> <p>* In combination with carboplatin and gemcitabine for treatment of adult patients with first recurrence of platinum-sensitive <b>epithelial ovarian, fallopian tube or primary peritoneal cancer</b> who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.</p>	12/01/2005	Roche Registration Limited
BENEFIX	Recombinant coagulation Factor IX INN = Nonacog alpha	Treatment and prophylaxis of bleeding in patients with <b>haemophilia B</b> (congenital factor IX deficiency).	27/08/1997	Pfizer Ltd
BIOGRASTIM	Filgrastim	In patients, children or adults, with <b>severe congenital, cyclic, or idiopathic neutropenia</b> with an absolute neutrophil count (ANC) of $\leq 0.5 \times 10^9/L$ , and a history of severe or recurrent infections, long term administration of Biograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.	15/09/2008	CT Arzneimittel GmbH
BUCCOLAM	Midazolam	Treatment of prolonged, acute, convulsive <b>seizures</b> in infants, toddlers, children and adolescents (from 3 months to < 18 years). Buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.	05/09/2011	ViroPharma SPRL
BUSILVEX	Busulfan (Intravenous use)	Followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional <b>haematopoietic progenitor cell transplantation</b> (HPCT) in adult patients when the combination is considered the best available option. Followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients.	09/07/2003	Pierre Fabre Médicament

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
CAELYX	Doxorubicin hydrochloride (pegylated liposomal)	<p>*For treatment of advanced <b>ovarian cancer</b> in women who have failed a first-line platinum-based chemotherapy regimen.</p> <p>*In combination with bortezomib for the treatment of progressive <b>multiple myeloma</b> in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.</p> <p>*Treatment of AIDS-related <b>Kaposi's sarcoma</b> (KS) in patients with low CD4 counts (&lt; 200 CD4 lymphocytes/mm<sup>3</sup>) and extensive mucocutaneous or visceral disease.</p>	21/06/1996	Janssen-Cilag International N.V.
CANCIDAS	Caspofungin	<p>Treatment of invasive <b>aspergillosis</b> in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and/or itraconazole.</p> <p>Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients.</p>	24/10/2001	Merck Sharp & Dohme Ltd
CAPRELSA	Vandetanib	<p>Treatment of aggressive and symptomatic medullary <b>thyroid cancer</b> (MTC) in patients with unresectable locally advanced or metastatic disease.</p> <p>For patients in whom Rearranged during Transfection (RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.</p>	17/02/2012	AstraZeneca AB
CEPROTIN	Human protein C	<p>*In purpura fulminans and coumarin-induced skin necrosis in patients with severe <b>congenital protein C deficiency</b>.</p> <p>*Short-term prophylaxis in patients with severe <b>congenital protein C deficiency</b> : if surgery or invasive therapy is imminent, while initiating coumarin therapy, when coumarin therapy alone is not sufficient, when coumarin therapy is not feasible.</p>	16/07/2001	Baxter AG
CEREZYME	Imiglucerase	<p>Long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (<b>Type 1</b>) or chronic neuronopathic (<b>Type 3</b>) <b>Gaucher disease</b> and who exhibit clinically significant non-neurological manifestations of the disease, including one or more of the following conditions: anaemia after exclusion of other causes, such as iron deficiency; thrombocytopenia; bone disease after exclusion of other causes such as Vitamin D deficiency; hepatomegaly or splenomegaly.</p>	17/11/1997	Genzyme Europe B.V.

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
CINRYZE	C1 inhibitor (human)	*Treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with <b>hereditary angioedema (HAE)</b> . *Routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of <b>hereditary angioedema (HAE)</b> , who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.	15/06/2011	ViroPharma SPRL
COLOBREATHE	Colistimethate sodium	Management of chronic pulmonary infections due to <i>Pseudomonas aeruginosa</i> in patients with <b>cystic fibrosis (CF)</b> aged 6 years and older.	13/02/2012	Forest Laboratories UK Ltd
CYSTAGON	Mercaptamine bitartrate	Treatment of proven nephropathic <b>cystinosis</b> . Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.	23/06/1997	Orphan Europe S.A.R.L.
DUKORAL	Vibrio cholerae and recombinant cholera toxin B-subunit	Active immunisation against <b>disease caused by Vibrio cholerae</b> serogroup O1 in adults and children from 2 years of age who will be visiting endemic/epidemic areas.	28/04/2004	Crucell Sweden AB
ENBREL	Etanercept	*Treatment of <b>polyarthritis</b> (rheumatoid-factorpositive or -negative) and extended <b>oligoarthritis</b> in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. *Treatment of <b>psoriatic arthritis</b> in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. *Treatment of <b>enthesitis-related arthritis</b> in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. Enbrel has not been studied in children aged less than 2 years.	03/02/2000	Pfizer Ltd
ERBITUX	Cetuximab	Treatment of patients with <b>squamous cell cancer of the head and neck</b> : - in combination with radiation therapy for locally advanced disease, - in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.	29/06/2004	Merck KGaA
EURARTESIM	Piperaquine tetraphosphate / dihydroartemisinin	Treatment of uncomplicated <b>Plasmodium falciparum malaria</b> in adults, children and infants 6 months and over and weighing 5 kg or more. Consideration should be given to official guidance on the appropriate use of antimalarial agents.	27/10/2011	Sigma-Tau Industrie Farmaceutiche Riunite S.p.A

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
FABRAZYME	Recombinant human alpha-galactosidase INN = Agalsidase beta	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of <b>Fabry disease</b> (alpha-galactosidase A deficiency).	03/08/2001	Genzyme Europe B.V.
FERRIPROX	Deferiprone	Treatment of iron overload in patients with <b>thalassaemia</b> major when deferoxamine therapy is contraindicated or inadequate.	25/08/1999	Apotex Europe B.V.
FILGRASTIM HEXAL	Filgrastim	In patients, children or adults, with <b>severe congenital, cyclic, or idiopathic neutropenia</b> with an absolute neutrophil count (ANC) of $\leq 0.5 \times 10^9/L$ , and a history of severe or recurrent infections.	06/02/2009	Hexal AG
FLEBOGAMMA DIF	Human normal immunoglobulin	<p>* Replacement therapy in adults, and children and adolescents (2-18 years) in:</p> <ul style="list-style-type: none"> <li>- <b>Primary immunodeficiency</b> (PID) syndromes with impaired antibody production.</li> <li>- <b>Hypogammaglobulinaemia</b> and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed.</li> <li>- <b>Hypogammaglobulinaemia</b> and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation.</li> <li>- <b>Hypogammaglobulinaemia</b> in patients after allogeneic haematopoietic stem cell transplantation (HSCT).</li> </ul> <p>* Immunomodulation in adults, and children and adolescents (2-18 years) in:</p> <ul style="list-style-type: none"> <li>- <b>Primary immune thrombocytopenia</b> (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count.</li> <li>- <b>Guillain-Barré syndrome,</b></li> <li>- <b>Kawasaki disease.</b></li> </ul>	23/07/2007	Instituto Grifols S.A.

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
GLIVEC	Imatinibmesilate	<p>* Treatment of :</p> <ul style="list-style-type: none"> <li>- adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) <b>chronic myeloid leukaemia</b> (CML) for whom bone marrow transplantation is not considered as the first line of treatment;</li> <li>- adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;</li> <li>- adult patients with newly diagnosed Philadelphia chromosome positive <b>acute lymphoblastic leukaemia</b> (Ph+ ALL) integrated with chemotherapy;</li> <li>- adult patients with relapsed or refractory Ph+ ALL as monotherapy;</li> <li>- adult patients with <b>myelodysplastic/ myeloproliferative diseases</b> (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;</li> <li>- adult patients with advanced <b>hypereosinophilic syndrome</b> (HES) and/or <b>chronic eosinophilic leukaemia</b> (CEL) with FIP1L1-PDGFR<math>\alpha</math> rearrangement;</li> <li>- adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant <b>gastrointestinal stromal tumours</b> (GIST);</li> <li>- adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive <b>GIST</b>. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;</li> <li>- adult patients with unresectable <b>dermatofibrosarcoma protuberans</b> (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.</li> </ul>	07/11/2001	Novartis Europharm Ltd
GONAL-F	Recombinant human follicle stimulating hormone INN = Follitropin alpha	Stimulation of spermatogenesis in men who have <b>congenital</b> or <b>acquired hypogonadotrophic hypogonadism</b> with concomitant human Chorionic Gonadotrophin (hCG) therapy.	20/10/1995	Merck Serono Europe Ltd
HELIXATE NEXGEN	Octocog alpha	Treatment and prophylaxis of bleeding in patients with <b>haemophilia A</b> (congenital factor VIII deficiency).	04/08/2000	Bayer Pharma AG



TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
HERCEPTIN	Trastuzumab	<p>*In combination with capecitabine or 5-fluorouracil and cisplatin, treatment of patients with HER2-positive metastatic <b>adenocarcinoma of the stomach or gastroesophageal junction</b> who have not received prior anticancer treatment for their metastatic disease.</p> <p>*Herceptin should only be used in patients with metastatic <b>gastric cancer</b> whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC3+ result. Accurate and validated assay methods should be used.</p>	28/08/2000	Roche Registration Limited
HIZENTRA	Human normal immunoglobulin (SCIg)	<p>* Replacement therapy in adults and children in <b>primary immunodeficiency syndromes</b> such as:</p> <ul style="list-style-type: none"> <li>- congenital <b>agammaglobulinaemia</b> and <b>hypogammaglobulinaemia</b>,</li> <li>- <b>common variable immunodeficiency</b>,</li> <li>- <b>severe combined immunodeficiency</b>,</li> <li>- <b>IgG subclass deficiencies</b> with recurrent infections.</li> </ul> <p>* Replacement therapy in <b>myeloma</b> or <b>chronic lymphocytic leukaemia</b> with severe secondary hypogammaglobulinaemia and recurrent infections.</p>	14/04/2011	CSL Behring GmbH
HUMIRA	Adalimumab	<p>*In combination with methotrexate is indicated for the treatment of active polyarticular <b>juvenile idiopathic arthritis</b>, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).</p> <p>*As monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate</p> <p>Humira has not been studied in children aged less than 2 years.</p>	08/09/2003	Abbott Laboratories Ltd

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
HYCAMTIN	Topotecan	<p><b>HYCAMTIN powder for concentrate for solution for infusion:</b>  *Monotherapy for the treatment of:  - patients with metastatic <b>carcinoma of the ovary</b> after failure of first-line or subsequent therapy.  - patients with relapsed <b>small cell lung cancer (SCLC)</b> for whom re-treatment with the first-line regimen is not considered appropriate.</p> <p>*In combination with cisplatin for patients with <b>carcinoma of the cervix</b> recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.</p> <p><b>HYCAMTIN capsules:</b>  As monotherapy for the treatment of adult patients with relapsed <b>small cell lung cancer (SCLC)</b> for whom re-treatment with the first-line regimen is not considered appropriate.</p>	12/11/1996	SmithKline Beecham Ltd
HYQVIA	Human normal immunoglobulin	<p>* Replacement therapy in adults (&gt; 18 years) in primary immunodeficiency syndromes such as:  - <b>congenital agammaglobulinaemia and hypogammaglobulinaemia</b>  - <b>common variable immunodeficiency</b>  - <b>severe combined immunodeficiency</b>  - <b>IgG subclass deficiencies</b> with recurrent infections.</p> <p>* Replacement therapy in adults (&gt; 18 years) in <b>myeloma or chronic lymphocytic leukaemia</b> with severe secondary hypogammaglobulinaemia and recurrent infections.</p>	16/05/2013	Baxter Innovations GmbH
ILARIS	Canakinumab	<p>Ilaris is indicated for the treatment of <b>Cryopyrin-Associated Periodic Syndromes (CAPS)</b> in adults, adolescents and children aged <b>2 years</b> and older with body weight of <b>7,5 kg</b> or above, including:  -Muckle-Wells Syndrome (MWS),  - Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA),  -Severe forms of Familial Cold Autoinflammatory Syndrome (FCAS) / Familial Cold Urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.</p>	23/10/2009	Novartis Europharm Ltd
INLYTA	Axitinib	For the treatment of adult patients with advanced <b>renal cell carcinoma (RCC)</b> after failure of prior treatment with sunitinib or a cytokine.	03/09/2012	Pfizer Ltd.

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
INOMAX	Nitric oxide	In conjunction with ventilatory support and other appropriate active substances: - for the treatment of newborn infants $\geq$ 34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of <b>pulmonary hypertension</b> , in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation. - as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.	01/08/2001	INO Therapeutics AB
INTRONA	Interferon alpha-2b	*Treatment of patients with <b>hairy cell leukaemia</b> Monotherapy treatment of adults with Philadelphia chromosome or bcr/abl translocation positive <b>chronic myelogenous leukaemia</b> . Combination therapy with cytarabine administered during the first 12 months of treatment has been demonstrated to significantly increase the rate of major cytogenetic responses and to significantly prolong the overall survival at three years when compared to interferon alfa-2b monotherapy *Treatment of patients with <b>multiple myeloma</b> , as maintenance therapy in patients who have achieved objective remission (more than 50 % reduction in myeloma protein) following initial induction chemotherapy. *Treatment of high tumour burden <b>follicular lymphoma</b> as adjunct to appropriate combination induction chemotherapy such as a CHOP-like regimen Treatment of carcinoid tumours with lymph node or liver metastases and with "carcinoid syndrome".	09/03/2000	Merck Sharp & Dohme Limited
IXIARO	Japanese Encephalitis Vaccine (inactivated, adsorbed)	For active immunization against <b>Japanese encephalitis</b> for adults, adolescents, children and infants aged 2 months and older.	31/03/2009	Intercell AG
KEPPRA	Levetiracetam	*As monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed <b>epilepsy</b> . *As adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, children and infants from <b>1 month</b> of age with epilepsy ; in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with <b>Juvenile Myoclonic Epilepsy</b> ; in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.	29/09/2000	UCB Pharma SA

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
KIOVIG	Human normal immunoglobulin	<p>*Replacement therapy in adults, and children and adolescents (0-18 years) in:</p> <ul style="list-style-type: none"> <li>- <b>Primary immunodeficiency syndromes</b> with impaired antibody production,</li> <li>- <b>Hypogammaglobulinaemia</b> and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed,</li> <li>- Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation,</li> <li>- Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (HSCT).</li> </ul> <p>*Immunomodulation in adults, and children and adolescents (0-18 years) in:</p> <ul style="list-style-type: none"> <li>- <b>Primary immune thrombocytopenia (ITP)</b>, in patients at high risk of bleeding or prior to surgery to correct the platelet count,</li> <li>- <b>Guillain Barré syndrome</b>,</li> <li>- <b>Kawasaki disease</b>,</li> <li>- <b>Multifocal Motor Neuropathy (MMN)</b>.</li> </ul>	19/01/2006	Baxter AG
KOGENATE BAYER	Octocog alpha	Treatment and prophylaxis of bleeding in patients with <b>haemophilia A</b> (congenital factor VIII deficiency).	04/08/2000	Bayer Pharma AG
MABTHERA	Rituximab	<p>Indicated in adults for:</p> <p>*Treatment of previously untreated patients with stage III-IV <b>follicular lymphoma</b> in combination with chemotherapy. Maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. Monotherapy is indicated for treatment of patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. Treatment of patients with CD20 positive <b>diffuse large B cell non-Hodgkin's lymphoma</b> in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.</p> <p>*In combination with chemotherapy, treatment of patients with previously untreated and relapsed/refractory <b>chronic lymphocytic leukaemia (CLL)</b>. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including MabThera or patients refractory to previous MabThera plus chemotherapy.</p>	02/06/1998	Roche Registration Limited
NIVESTIM	Filgrastim	In patients, children or adults, with <b>severe congenital, cyclic, or idiopathic neutropenia</b> with an absolute neutrophil count (ANC) of $\leq 0.5 \times 10^9/L$ , and a history of severe or recurrent infections.	08/06/2010	Hospira UK Ltd

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
NOVOSEVEN	Human recombinant coagulation Factor VIIa INN = Eptacog alpha (activated)	Treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups : in patients with congenital <b>haemophilia</b> with inhibitors to coagulation factors VIII or IX > 5 BU; in patients with congenital <b>haemophilia</b> who are expected to have a high anamnestic response to factor VIII or factor IX administration; in patients with <b>acquired haemophilia</b> ; in patients with <b>congenital FVII deficiency</b> ; in patients with <b>Glanzmann's thrombasthenia</b> with antibodies to GP IIB - IIIa and/or HLA, and with past or present refractoriness to platelet transfusions.	23/02/1996	Novo Nordisk A/S
NOVOTHIRTEEN	Catridecacog	Long term prophylactic treatment of bleeding in patients 6 years and above with <b>congenital factor XIII A-subunit deficiency</b> .	03/09/2012	Novo Nordisk A/S
NOXAFIL	Posaconazole	*Treatment of the fungal infections in adults: - Invasive <b>aspergillosis</b> in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products, - <b>Fusariosis</b> in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B.- <b>Chromoblastomycosis</b> and <b>mycetoma</b> in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole, - <b>Coccidioidomycosis</b> in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. *Prophylaxis of invasive fungal infections in : - Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections, - Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.	25/10/2005	Merck Sharp & Dohme Ltd.
NUEDEXTA	Dextromethorphan hydrobromide / Quinidine INN = Dextromethorphan hydrobromide / Quinidine sulfate	For the symptomatic treatment of pseudobulbar affect (PBA) in adults. Efficacy has been studied in patients with underlying <b>Amyotrophic Lateral Sclerosis</b> .	24/06/2013	Jenson Pharmaceutical Services Limited

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
OMNITROPE	Somatropin	<p>* Infants, children and adolescents:</p> <ul style="list-style-type: none"> <li>- Growth disturbance due to <b>insufficient secretion of growth hormone (GH)</b>,</li> <li>- Growth disturbance associated with <b>Turner syndrome</b>,</li> <li>- Growth disturbance (current height standard deviation score (SDS) &lt; -2,5 and parental adjusted SDS &lt; -1) in short children/adolescents born small for gestational age (SGA), with a birth weight and/or length below -2 standard deviation (SD), who failed to show catch-up growth (height velocity (HV) SDS &lt; 0 during the last year) by 4 years of age or later,</li> <li>- <b>Prader-Willi syndrome (PWS)</b>, for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.</li> </ul> <p>* Adults:</p> <ul style="list-style-type: none"> <li>- Replacement therapy in adults with pronounced <b>growth hormone deficiency</b>. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low IGF-I concentrations (SDS &lt; -2) who may be considered for one test. The cut-off point of the dynamic test should be strict.</li> </ul>	12/04/2006	Sandoz GmbH
ORENCIA	Abatacept	In combination with methotrexate, for the treatment of moderate to severe active <b>polyarticular juvenile idiopathic arthritis (JIA)</b> in paediatric patients 6 years of age and older who have had an insufficient response to other DMARDs including at least one TNF inhibitor.	21/05/2007	Bristol-Myers Squibb Pharma EEIG
OZURDEX	Dexamethasone	For the treatment of adult patients with <b>inflammation of the posterior segment of the eye</b> presenting as <b>non-infectious uveitis</b> .	27/07/2010	Allergan Pharmaceuticals Ireland
PANRETIN	Alitretinoin	Topical treatment of cutaneous lesions in patients with AIDS-related <b>Kaposi's sarcoma (KS)</b> : when lesions are not ulcerated or lymphoedematous, and treatment of visceral KS is not required, and when lesions are not responding to systemic antiretroviral therapy, and radiotherapy or chemotherapy are not appropriate.	11/10/2000	Eisai Ltd

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
PIXUVRI	Pixantrone dimaleate	As monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive <b>non-Hodgkin B cell lymphomas</b> (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.	10/05/2012	CTI Life Sciences Ltd
PRIVIGEN	Human normal immunoglobulin (IVIg)	* Replacement therapy in adults, and children and adolescents (0-18 years) in: - <b>Primary immunodeficiency</b> (PID) syndromes with impaired antibody production, - <b>Hypogammaglobulinaemia</b> and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed, - <b>Hypogammaglobulinaemia</b> and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunization, - <b>Hypogammaglobulinaemia</b> in patients after allogeneic haematopoietic stem cell transplantation (HSCT), * Immunomodulation in adults, and children and adolescents (0-18 years) in: - <b>Primary immune thrombocytopenia</b> (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count, - <b>Guillain-Barré syndrome</b> , - <b>Kawasaki disease</b> , - <b>Chronic inflammatory demyelinating polyneuropathy</b> (CIDP). Only limited experience is available of use of intravenous immunoglobulins in children with CIDP.	25/04/2008	CSL Behring GmbH
PUREGON	Follitropin beta	Treatment of deficient spermatogenesis due to <b>hypogonadotrophic hypogonadism</b> .	03/05/1996	NV Organon
RATIOGRASTIM	Filgrastim	In patients, children or adults, with <b>severe congenital, cyclic, or idiopathic neutropenia</b> with an absolute neutrophil count (ANC) of $\leq 0.5 \times 10^9/L$ , and a history of severe or recurrent infections.	15/09/2008	Ratiopharm GmbH
REFACTO AF	Moroctocog alpha	Treatment and prophylaxis of bleeding in patients with <b>haemophilia A</b> (congenital factor VIII deficiency) in adults and children of all ages, including newborns.	13/04/1999	Pfizer Ltd
REPLAGAL	Agalsidase alfa	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of <b>Fabry Disease</b> (alpha-galactosidase A deficiency)	03/08/2001	Shire Human Genetic Therapies AB
REVOLADE	Eltrombopag	For adult chronic <b>immune (idiopathic) thrombocytopenic purpura (ITP)</b> splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Revolade may be considered as second line treatment for adult non-splenectomised patients where surgery is contraindicated.	11/03/2010	Glaxo-SmithKline Trading Services Limited

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
RILUTEK	Riluzole	To extend life or the time to mechanical ventilation for patients with <b>amyotrophic lateral sclerosis (ALS)</b> .	10/06/1996	Aventis Pharma S.A.
ROACTEMRA	Tocilizumab	Treatment of active <b>systemic juvenile idiopathic arthritis (sJIA)</b> in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.	16/01/2009	Roche Registration Ltd
RUCONEST	Conestat alfa	Treatment of acute angioedema attacks in adults with <b>hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency</b> .	28/10/2010	Pharming Group N.V.
SAMSCA	Tolvaptan	Treatment of adult patients with hyponatraemia secondary to <b>syndrome of inappropriate antidiuretic hormone secretion (SIADH)</b> .	03/08/2009	Otsuka Pharmaceutical Europe Ltd
SOMAVERT	Pegvisomant	Treatment of patients with <b>acromegaly</b> who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerate.	13/11/2002	Pfizer Ltd
STAYVEER	Bosentan monohydrate	* For the treatment of <b>pulmonary arterial hypertension (PAH)</b> to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in: - Primary (idiopathic and heritable) PAH ; - PAH secondary to scleroderma without significant interstitial pulmonary disease ; - PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology. Some improvements have also been shown in patients with PAH WHO functional class II. * To reduce the number of new digital ulcers in patients with <b>systemic sclerosis</b> and ongoing digital ulcer disease.	24/06/2013	Marklas Nederland BV
SUTENT	Sunitinib	*Treatment of unresectable and/or metastatic malignant <b>gastrointestinal stromal tumour (GIST)</b> after failure of imatinib mesilate treatment due to resistance or intolerance. *Treatment of advanced/metastatic <b>renal cell carcinoma (MRCC)</b> in adults. *Treatment of unresectable or metastatic, well-differentiated <b>pancreatic neuroendocrine tumours (pNET)</b> with disease progression in adults Experience with SUTENT as first-line treatment is limited.	19/07/2006	Pfizer Limited




TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
TARCEVA	Erlotinib	In combination with gemcitabine, for the treatment of patients with metastatic <b>pancreatic cancer</b> . When prescribing Tarceva, factors associated with prolonged survival should be taken into account. No survival advantage could be shown for patients with locally advanced disease.	19/09/2005	Roche Registration Limited
TARGRETIN	Bexarotene	Treatment of skin manifestations of advanced stage <b>cutaneous T-cell lymphoma</b> (CTCL) patients refractory to at least one systemic treatment.	29/03/2001	Eisai Ltd
TAXOTERE	Docetaxel	*In combination with cisplatin and 5-fluorouracil for the treatment of patients with metastatic <b>gastric adenocarcinoma</b> , including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease *In combination with cisplatin and 5-fluorouracil for the induction treatment of patients with locally advanced <b>squamous cell carcinoma of the head and neck</b> .	27/11/1995	Aventis Pharma S.A.
TEMODAL	Temozolomide	*Treatment of adult patients with newly-diagnosed <b>glioblastoma</b> multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment. *Treatment of children from the age of three years, adolescents and adult patients with <b>malignant glioma</b> , such as <b>glioblastoma</b> multiforme or anaplastic <b>astrocytoma</b> , showing recurrence or progression after standard therapy.	26/01/1999	Merck Sharp & Dohme Ltd.
TEVAGRASTIM	Filgrastim	In patients, children or adults, with <b>severe congenital, cyclic, or idiopathic neutropenia</b> with an absolute neutrophil count (ANC) of $\leq 0.5 \times 10^9/L$ , and a history of severe or recurrent infections.	15/09/2008	Teva Generics GmbH
TEYSUNO	Tegafur/Gimeracil /Oteracil	In adults for the treatment of advanced <b>gastric cancer</b> when given in combination with cisplatin.	14/03/2011	Nordic Group BV

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
THYROGEN	Thyrotropin alfa	For use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and <b>well-differentiated thyroid cancer</b> in post-thyroidectomy patients maintained on hormone suppression therapy (THST). Low-risk patients with well-differentiated thyroid carcinoma who have undetectable serum Tg levels on THST and no rh (recombinant human) TSH-stimulated increase of Tg levels may be followed-up by assaying rh TSH-stimulated Tg levels. For pre-therapeutic stimulation in combination with a range of 30 mCi (1.1 GBq) to 100 mCi (3.7 GBq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for <b>well-differentiated thyroid cancer</b> and who do not have evidence of distant metastatic thyroid cancer.	09/03/2000	Genzyme Europe B.V.
TRISENOX	Arsenic trioxide	Induction of remission and consolidation in adult patients with relapsed/refractory <b>acute promyelocytic leukaemia</b> (APL), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid Receptor-alpha (PML/RAR-alpha) gene. Previous treatment should have included a retinoid and chemotherapy.	05/03/2002	Cephalon Europe
VEDROP	Tocofersolan	Indicated in vitamin E deficiency due to digestive malabsorption in paediatric patients with <b>congenital chronic cholestasis</b> or <b>hereditary chronic cholestasis</b> , from birth (full term newborns) up to 18 years of age.	24/07/2009	Orphan Europe S.A.R.L
VELCADE	Bortezomib	*In combination with melphalan and prednisone, treatment of adult patients with previously untreated <b>multiple myeloma</b> who are not eligible for high-dose chemotherapy with bone marrow transplant. *As monotherapy for the treatment of progressive <b>multiple myeloma</b> in adult patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation.	26/04/2004	Janssen-Cilag International NV
VFEND	Voriconazole	In adults and children aged 2 years and above as follows: - treatment of invasive <b>aspergillosis</b> . - treatment of <b>serious fungal infections</b> caused by <i>Scedosporium spp.</i> and <i>Fusarium spp.</i> Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.	19/03/2002	Pfizer Limited

TRADENAME	ACTIVE SUBSTANCE	MARKETING AUTHORISATION INDICATION	MARKETING AUTHORISATION DATE (DD/MM/YYYY)	MARKETING AUTHORISATION HOLDER
VOTRIENT	Pazopanib	*In adults for the first-line treatment of advanced <b>renal cell carcinoma (RCC)</b> and for patients who have received prior cytokine therapy for advanced disease. *For the treatment of adult patients with selective subtypes of advanced <b>soft-tissue sarcoma (STS)</b> who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)-adjuvant therapy. Efficacy and safety have only been established in certain STS histological tumour subtypes.	14/06/2010	Glaxo Group Ltd
XELODA	Capecitabine	First-line treatment of advanced <b>gastric cancer</b> in combination with a platinum-based regimen	02/02/2001	Roche Registration Limited
XYREM	Sodium oxybate	Treatment of <b>narcolepsy with cataplexy</b> in adult patients.	13/10/2005	UCB Pharma Ltd
ZARZIO	Filgrastim	In children and adults with <b>severe congenital, cyclic, or idiopathic neutropenia</b> with an absolute neutrophil count (ANC) of $\leq 0.5 \times 10^9/L$ , and a history of severe or recurrent infections, long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.	06/02/2009	Sandoz GmbH
ZEVALIN	Ibritumomab tiuxetan	*Consolidation therapy after remission induction in previously untreated patients with <b>follicular lymphoma</b> . *Treatment of adult patients with rituximab relapsed or refractory CD20+ <b>follicular B-cell non-Hodgkin's lymphoma (NHL)</b> .	16/01/2004	Spectrum Pharmaceuticals B.V.
ZUTECTRA	Human Hepatitis B Immunoglobulin	Prevention of <b>hepatitis B virus (HBV) re-infection</b> in HBV-DNA negative patients over 6 months <b>after liver transplantation for hepatitis B induced liver failure</b> . Zutectra is indicated in adults only. The concomitant use of adequate virostatic agents should be considered, if appropriate, as standard of hepatitis B re-infection prophylaxis.	30/11/2009	Biotest Pharma GmbH

## Classificazione per data dell'AIC in ordine decrescente


<b>2013</b>	<b>2009</b>	<b>2005</b>	<b>2001</b>	<b>1998</b>
HYQVIA	AFINITOR	AVASTIN	CANCIDAS	MABTHERA
NUEDEXTA	FILGRASTIM HEXAL	NOXAFIL	CEPROTIN	<b>1997</b>
STAYVEER	ILARIS	TARCEVA	FABRAZYME	BENEFIX
<b>2012</b>	IXIARO	XYREM	GLIVEC	CEREZYME
CAPRELSA	ROACTEMRA	<b>2004</b>	INOMAX	CYSTAGON
COLOBREATHE	SAMSCA	ADVATE	REPLAGAL	<b>1996</b>
INLYTA	VEDROP	ALIMTA	TARGETIN	CAELYX
NOVOTHIRTEEN	ZARZIO	DUKORAL	XELODA	HYCAMTIN
PIXUVRI	ZUJECTRA	ERBITUX	<b>2000</b>	NOVOSEVEN
<b>2011</b>	<b>2008</b>	VELCADE	ENBREL	PUREGON
BUCCOLAM	ADCIRCA	ZEVALIN	HELIXATE NEXGEN	RILUTEK
CINRYZE	BIOGRASTIM	<b>2003</b>	HERCEPTIN	<b>1995</b>
EURARTESIM	PRIVIGEN	ALDURAZYME	INTRONA	GONAL-F
HIZENTRA	RATIOGRASTIM	BUSILVEX	KEPPRA	TAXOTERE
TEYSUNO	TEVAGRASTIM	HUMIRA	KOGENATE BAYER	
<b>2010</b>	<b>2007</b>	<b>2002</b>	PANRETIN	
NIVESTIM	FLEBOGAMMA DIF	SOMAVERT	THYROGEN	
OZURDEX	ORENCIA	TRISENOX	<b>1999</b>	
REVOLADE	<b>2006</b>	VFEND	AMMONAPS	
RUCONEST	ATRYN		FERRIPROX	
VOTRIENT	KIOVIG		REFACTO AF	
	OMNITROPE		TEMODAL	
	SUTENT			



## Classificazione per categoria ATC

<b>A- ALIMENTARY TRACT AND METABOLISM</b>	<b>G- GENITO URINARY SYSTEM AND SEX HORMONES</b>	ALIMTA	TEMODAL
ALDURAZYME	ADCIRCA	AVASTIN	TEVAGRASTIM
AMMONAPS	GONAL-F	BIOGRASTIM	TEYSUNO
CEREZYME	PUREGON	BUSILVEX	TRISENOX
CYSTAGON	<b>H- SYSTEMIC HORMONAL PREPARATIONS, EXCL, SEX HORMONES AND INSULINS</b>	CAELYX	VELCADE
FABRAZYME	OMNITROPE	CAPRELSA	VOTRIENT
REPLAGAL	SOMAVERT	ENBREL	XELODA
VEDROP	THYROGEN	ERBITUX	ZARZIO
<b>B- BLOOD AND BLOOD FORMING ORGANS</b>	<b>J- GENERAL ANTIINFECTIVES FOR SYSTEMIC USE</b>	FILGRASTIM HEXAL	<b>N- NERVOUS SYSTEM</b>
ADVATE	CANCIDAS	GLIVEC	BUCCOLAM
ATRYN	DUKORAL	HERCEPTIN	KEPPRA
BENEFIX	FLEBOGAMMA DIF	HUMIRA	NUEDEXTA
CEPROTIN	HIZENTRA	HYCAMTIN	RILUTEK
CINRYZE	HYQVIA	ILARIS	XYREM
HELIXATE NEXGEN	IXIARO	INLYTA	<b>P- ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS</b>
KOGENATE BAYER	KIOVIG	INTRONA	EURARTESIM
NOVOSEVEN	NOXAFIL	MABTHERA	<b>R- RESPIRATORY SYSTEM</b>
NOVOTHIRTEEN	PRIVIGEN	NIVESTIM	COLOBREATHE
REFACTO AF	VFEND	ORENCIA	INOMAX
REVLADE	ZUTECTRA	PANRETIN	<b>S- SENSORY ORGANS</b>
RUCONEST	<b>L- ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</b>	PIXUVRI	OSURDEX
<b>C- CARDIOVASCULAR SYSTEM</b>	AFINITOR	RATIOGRASTIM	<b>V- VARIOUS</b>
SAMSCA		ROACTEMRA	FERRIPROX
STAYVEER		SUTENT	ZEVALIN
		TARCEVA	
		TARGRETIN	
		TAXOTERE	

Numero dei farmaci orfani in Europa con autorizzazione all'immissione in commercio europea senza designazione orfana europea precedente per categoria ATC



## Classificazione per titolare dell'AIC

<b>ABBOTT LABORATORIES LTD</b>
HUMIRA
<b>ALLERGAN PHARMACEUTICALS IRELAND</b>
OZURDEX
<b>APOTEX EUROPE B.V.</b>
FERRIPROX
<b>ASTRAZENECA AB</b>
CAPRELSA
<b>AVENTIS PHARMA S.A.</b>
RILUTEK
TAXOTERE
<b>BAXTER AG</b>
ADVATE
CEPROTIN
KIOVIG
<b>BAXTER INNOVATIONS GMBH</b>
HYQVIA
<b>BAYER PHARMA AG</b>
HELIXATE NEXGEN
KOGENATE BAYER
<b>BIOTEST PHARMA GMBH</b>
ZUTECTRA
<b>BRISTOL-MYERS SQUIBB PHARMA EEIG</b>
ORENCIA
<b>CEPHALON EUROPE</b>
TRISENOX
<b>CRUCELL SWEDEN AB</b>
DUKORAL
<b>CSL BEHRING GMBH</b>
HIZENTRA
PRIVIGEN
<b>CT ARZNEIMITTEL GMBH</b>
BIOGRASTIM
<b>CTI LIFE SCIENCES LTD</b>
PIXUVRI
<b>EISAI LTD</b>
PANRETIN
TARGETIN

<b>ELI LILLY NEDERLAND B.V.</b>
ADCIRCA
ALIMTA
<b>FOREST LABORATORIES UK LTD</b>
COLOBREATHE
<b>GENZYME EUROPE B.V.</b>
ALDURAZYME
CEREZYME
FABRAZYME
THYROGEN
<b>GLAXO GROUP LTD</b>
VOTRIENT
<b>GLAXOSMITHKLINE TRADING SERVICES LIMITED</b>
REVOLADE
<b>GTC BIOTHERAPEUTICS UK LIMITED</b>
ATRYN
<b>HEXAL AG</b>
FILGRASTIM HEXAL
<b>HOSPIRA UK LTD</b>
NIVESTIM
<b>INO THERAPEUTICS AB</b>
INOMAX
<b>INSTITUTO GRIFOLS S.A.</b>
FLEBOGAMMA DIF
<b>INTERCELL AG</b>
IXIARO
<b>JANSSEN-CILAG INTERNATIONAL NV</b>
CAELYX
VELCADE
<b>JENSON PHARMACEUTICALS SERVICES LIMITED</b>
NUDEXTA
<b>MARKLAS NEDERLAND BV</b>
<b>STAYVEER</b>
<b>MERCK KGAA</b>
ERBITUX

<b>MERCK SERONO EUROPE LTD</b>
GONAL-F
<b>MERCK SHARP &amp; DOHME LTD</b>
CANCIDAS
INTRONA
NOXAFIL
TEMODAL
<b>NORDIC GROUP BV</b>
TEYSUNO
<b>NOVARTIS EUROPHARM LTD</b>
AFINITOR
GLIVEC
ILARIS
<b>NOVO NORDISK A/S</b>
NOVOSEVEN
NOVOTHIRTEEN
<b>NV ORGANON</b>
PUREGON
<b>ORPHAN EUROPE S.A.R.L.</b>
CYSTAGON
VEDROP
<b>OTSUKA PHARMACEUTICAL EUROPE LTD</b>
SAMSCA
<b>PFIZER LTD</b>
BENEFIX
ENBREL
INLYTA
REFACTO AF
SOMAVERT
SUTENT
VFEND
<b>PHARMING GROUP N.V.</b>
RUCONEST
<b>PIERRE FABRE MÉDICAMENTS</b>
BUSILVEX

<b>RATIOPHARM GMBH</b>
RATIOGRASTIM
<b>ROCHE REGISTRATION LTD</b>
AVASTIN
HERCEPTIN
MABTHERA
ROACTEMRA
TARCEVA
XELODA
<b>SANDOZ GMBH</b>
OMNITROPE
ZARZIO
<b>SHIRE HUMAN GENETIC THERAPIES AB</b>
REPLAGAL
<b>SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.</b>
EURARTESIM
<b>SMITHKLINE BEECHAM LTD</b>
HYCANTIN
<b>SPECTRUM PHARMACEUTICALS B.V.</b>
ZEVALIN
<b>SWEDISH ORPHAN BIOVITRUM INTERNATIONAL AB</b>
AMMONAPS
<b>TEVA GENERICS GMBH</b>
TEVAGRASTIM
<b>UCB PHARMA LTD</b>
XYREM
<b>UCB PHARMA SA</b>
KEPPRA
<b>VIROPHARMA SPRL</b>
BUCCOLAM
CINRYZE

Editors : Virginie Hivert & Marie-Pierre Bécas-Garro ● Visual design : Céline Angin ● Photography: M. Depardieu/Inserm

*The correct form when quoting this document is:*

« Elenchi dei prodotti medicinali per le malattie rare in Europa », I Quaderni di Orphanet, *collezione Farmaci Orfani*, Luglio 2013,  
[http://www.orpha.net/orphacom/cahiers/docs/IT/elenco\\_dei\\_farmaci\\_orfani\\_in\\_europa.pdf](http://www.orpha.net/orphacom/cahiers/docs/IT/elenco_dei_farmaci_orfani_in_europa.pdf)